YR0110
Human TRAIL Monoclonal Antibody
Size
£486.00
- SKU:
- YR0110
- Additional Names:
- Apo-2L|APO2L|CD253|TANCR|TL2|TNLG6A|TRAIL
- Application:
- ELISA, FuncS, Neutralisation
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- Abclonal
- Immunogen:
- Human TRAIL
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- P50591
- Synonyms:
- Apo-2 ligand;Apo-2L;APO2L;CD253;chemokine tumor necrosis factor ligand superfamily member 10;TL2;TNF-related apoptosis inducing ligand TRAIL;TNF-related apoptosis-inducing ligand;TNLG6A;TRAIL;tumor necrosis factor (ligand) family, member 10;tumor necrosis factor (ligand) superfamily, member 10;tumor necrosis factor apoptosis-inducing ligand splice variant delta;tumor necrosis factor ligand 6A;tumor necrosis factor ligand superfamily member 10;tumor necrosis factor superfamily member 10
- Extra Details:
- Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.
- Shipping Conditions:
- Blue Ice